Screening thousands of Pseudomonas mutants pins a stress-linked tRNA mark on the enzyme AvaS

AvaS acts on a base that has already been modified once. The release says the enzyme uses pyridoxal phosphate, a vitamin B6 derivative, to turn lysidine, written k2C, into ava2C ^[6]. PLP-dependent enzymes come with a long catalogue behind them, and until now that catalogue was amino acid metabolism and related pathways ^[7].

The route to the gene was a screen. SMART's platform measures RNA modifications by liquid chromatography-tandem mass spectrometry, so the readout is the chemical mark itself, and the platform was reported earlier in Nucleic Acids Research ^[5]. Thousands of Pseudomonas aeruginosa mutants went through it, and the mutant whose tRNA had lost ava2C named the gene ^[5]. A screen like that establishes that the gene is required for the modification in living cells. The paper's title claims the harder thing, biosynthesis of aminovaleramide by AvaS in tRNA ^[2], and the release describes AvaS carrying out the conversion with PLP ^[6].

The antimicrobial framing belongs to the release, which says the work opens avenues to study bacterial adaptation and to identify future targets for antimicrobial therapeutics ^[3]. P. aeruginosa earns that attention on its own record, since it causes serious infections including pneumonia and sepsis ^[10]. Getting from here to a target class needs three things this announcement does not report: what happens to the bacterium when avaS is deleted, whether losing ava2C moves antibiotic susceptibility, and whether any human enzyme performs comparable chemistry on a comparable site.

Counting the organisms in the paper helps with the last question, though it does not answer it. Add the pathogen where AvaS was found to the three where the team confirmed ava2C, and the modification is now reported in four named organisms, three bacterial and one plant ^[12]. Arabidopsis thaliana carrying ava2C shows the chemistry is not confined to bacteria ^[8]. Whether the plant enzyme resembles AvaS closely enough to matter to a medicinal chemist is not something the release addresses.

The functional claim carries no numbers. ava2C changes how bacteria read the genetic code and lets them produce proteins faster and more efficiently, according to the release ^[9], and the modification is described as linked to how bacteria respond to metabolic stress ^[1]. How much faster, and under which stress, is not stated. What the work adds without qualification is a chemistry: PLP-dependent enzymes now sit alongside methylation, thiolation and isomerization in the set of mechanisms known to modify bacterial tRNA ^[11].